Artivion (NYSE:AORT) Earns Outperform Rating from Analysts at JMP Securities

JMP Securities began coverage on shares of Artivion (NYSE:AORT) in a research note issued to investors on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $33.00 price target on the stock.

Other analysts also recently issued reports about the stock. Oppenheimer lifted their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Stifel Nicolaus lifted their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Artivion in a report on Friday, September 27th. Finally, Lake Street Capital lifted their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has an average rating of “Buy” and a consensus target price of $30.60.

Artivion Stock Down 0.5 %

Shares of Artivion stock opened at $26.47 on Wednesday. The stock has a market capitalization of $1.10 billion, a price-to-earnings ratio of -110.29 and a beta of 1.74. Artivion has a twelve month low of $12.16 and a twelve month high of $29.24. The company has a current ratio of 5.63, a quick ratio of 4.04 and a debt-to-equity ratio of 1.07. The business’s 50 day simple moving average is $25.90 and its 200-day simple moving average is $24.64.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, August 8th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.04. The firm had revenue of $98.02 million for the quarter, compared to analyst estimates of $97.70 million. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. Equities research analysts forecast that Artivion will post 0.2 earnings per share for the current year.

Insider Transactions at Artivion

In related news, CAO Amy Horton sold 12,430 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total value of $325,417.40. Following the completion of the sale, the chief accounting officer now owns 139,989 shares in the company, valued at $3,664,912.02. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $24.99, for a total value of $242,627.91. Following the transaction, the director now directly owns 34,159 shares in the company, valued at approximately $853,633.41. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 37,109 shares of company stock valued at $951,935. Company insiders own 8.10% of the company’s stock.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently added to or reduced their stakes in AORT. Creative Planning grew its position in Artivion by 182.1% in the third quarter. Creative Planning now owns 28,635 shares of the company’s stock worth $762,000 after buying an additional 18,486 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Artivion in the 3rd quarter worth $450,000. Perceptive Advisors LLC raised its holdings in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after buying an additional 124,725 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Artivion by 3.2% during the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after acquiring an additional 481 shares during the period. Finally, Marshall Wace LLP acquired a new stake in Artivion during the 2nd quarter valued at $366,000. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.